House Bill 502

Last Action 02/21/19: to Banking & Insurance (H)
Title AN ACT relating to prescription drugs.
Bill Documents Introduced
Bill Request Number 1271
Sponsor D. Bentley
Summary of Original Version Create new sections of KRS Chapter 217 to define terms; require the Cabinet for Health and Family Services to annually compile a list of certain prescription drugs deemed to be essential to treating diabetes and a list of such drugs that have been subject to a price increase greater than a certain percentage; require drug manufacturers to annually report to the cabinet certain information related to the cost of manufacturing and marketing such drugs and factors that contributed to a price increase; require pharmacy benefit managers to annually report to the cabinet certain information related to prescription drug rebates for such drugs; exempt such information and data reported by manufacturers and pharmacy benefit managers to the cabinet from disclosure pursuant to KRS 61.870 to 61.884; require the cabinet to annually submit to the Legislative Research Commission a report that summarizes the information reported to the cabinet by manufacturers and pharmacy benefit managers; require the cabinet to promulgate administrative regulations necessary to carry out the new sections; amend KRS 217.990 to establish a penalty for failure to report; amend KRS 304.17A-164 to restrict cost-sharing amounts charged by insurers and pharmacy benefit managers; prohibit insurers and pharmacy benefit managers from restricting a pharmacist's ability to inform patients about and to sell less expensive alternative drugs; and amend KRS 304.17A-505 and 304.17C-030 to require disclosure of information related to drug formularies.
Index Headings of Original Version Diseases - Diabetes, insulin price reporting requirements, establishing
Drugs and Medicines - Insulin, price reporting requirements, establishing
Insurance, Health - Cost-sharing amounts, restricting
Insurance, Health - Drug formulary disclosure, requiring
Pharmacists - Sale of less expensive alternative drugs, permitting
Administrative Regulations and Proceedings - Cabinet for Health and Family Services, prescription drug price reporting
Reports Mandated - Cabinet for Health and Family Services, insulin drug prices


  • introduced in House
  • to Banking & Insurance (H)

Last updated: 11/9/2023 3:08 PM (EST)